Market Overview

FDA Says Analysis of Pfizer's Chantix Increased CVE Risk Not Statistical Significant

Related PFE
UPDATE: Pfizer Posts Upbeat Q2 Results, Shares Gain
#PreMarket Primer: Tuesday, July 29: Russia Accused Of Violating Nuclear Treaty
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

The U.S. FDA is informing the public about the results of a large, combined analysis (called a meta-analysis) of clinical trials that compared patients who received the smoking cessation drug Chantix (varenicline) to patients who received a placebo (an inactive treatment). FDA required the manufacturer of Chantix to conduct the meta-analysis to further evaluate the cardiovascular safety of the drug, and believes it is important to let health care professionals and patients know about the results of this study. FDA first notified the public about a possible increased risk of cardiovascular adverse events with Chantix in its June 2011 Drug Safety Communication (DSC)3.

Posted-In: News FDA

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters